- Home
- TSI vs IMAB Comparison
TSI vs IMAB Comparison
Compare TSI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- IMAB
- Stock Information
- Founded
- TSI 1987
- IMAB 2014
- Country
- TSI United States
- IMAB United States
- Employees
- TSI N/A
- IMAB N/A
- Industry
- TSI Investment Managers
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- IMAB Health Care
- Exchange
- TSI Nasdaq
- IMAB Nasdaq
- Market Cap
- TSI 234.6M
- IMAB 200.9M
- IPO Year
- TSI N/A
- IMAB 2020
- Fundamental
- Price
- TSI $4.88
- IMAB $2.45
- Analyst Decision
- TSI
- IMAB Strong Buy
- Analyst Count
- TSI 0
- IMAB 2
- Target Price
- TSI N/A
- IMAB $6.00
- AVG Volume (30 Days)
- TSI 106.8K
- IMAB 1.2M
- Earning Date
- TSI 01-01-0001
- IMAB 05-15-2025
- Dividend Yield
- TSI 7.46%
- IMAB N/A
- EPS Growth
- TSI N/A
- IMAB N/A
- EPS
- TSI N/A
- IMAB N/A
- Revenue
- TSI N/A
- IMAB N/A
- Revenue This Year
- TSI N/A
- IMAB N/A
- Revenue Next Year
- TSI N/A
- IMAB N/A
- P/E Ratio
- TSI N/A
- IMAB N/A
- Revenue Growth
- TSI N/A
- IMAB N/A
- 52 Week Low
- TSI $4.48
- IMAB $0.60
- 52 Week High
- TSI $4.87
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- TSI 59.90
- IMAB 50.05
- Support Level
- TSI $4.80
- IMAB $2.35
- Resistance Level
- TSI $4.97
- IMAB $2.59
- Average True Range (ATR)
- TSI 0.04
- IMAB 0.35
- MACD
- TSI 0.00
- IMAB -0.06
- Stochastic Oscillator
- TSI 84.21
- IMAB 1.86
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).